Skip to content 
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers, by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas, as well as develops a data analytics and artificial intelligence platform to integrate diverse data sets into actionable insights that support precision oncology, therapeutic development, and clinical decision-making. The company was formerly known as Plus Therapeutics, Inc. and changed its name to Cerenome, Inc. in August 2026. Cerenome, Inc. was founded in 1996 and is headquartered in Houston, Texas. more
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |||
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |
| Cost of Revenue | - | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |
| Gross Profit | - | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |
| Gross Margin | - | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |
| Operating Expenses | 19.71M | 13.32M | 14.70M | 15.30M | [{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":67.58,"profit":true},{"date":"2024-12-31","value":74.55,"profit":true},{"date":"2025-12-31","value":77.61,"profit":true}] | |
| Operating Income | (19.71M) | (13.32M) | (14.70M) | (15.30M) | [{"date":"2022-12-31","value":-1971200000,"profit":false},{"date":"2023-12-31","value":-1332100000,"profit":false},{"date":"2024-12-31","value":-1469500000,"profit":false},{"date":"2025-12-31","value":-1529800000,"profit":false}] | |
| Total Non-Operating Income/Expense | (563.00K) | - | 1.72M | (7.09M) | [{"date":"2022-12-31","value":-32.79,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":-412.81,"profit":false}] | |
| Pre-Tax Income | (20.27M) | (13.32M) | (12.98M) | (22.39M) | [{"date":"2022-12-31","value":-2027500000,"profit":false},{"date":"2023-12-31","value":-1331600000,"profit":false},{"date":"2024-12-31","value":-1297800000,"profit":false},{"date":"2025-12-31","value":-2238600000,"profit":false}] | |
| Income Taxes | - | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |
| Income After Taxes | - | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |
| Income From Continuous Operations | (20.27M) | (13.32M) | (12.98M) | (22.39M) | [{"date":"2022-12-31","value":-2027500000,"profit":false},{"date":"2023-12-31","value":-1331600000,"profit":false},{"date":"2024-12-31","value":-1297800000,"profit":false},{"date":"2025-12-31","value":-2238600000,"profit":false}] | |
| Income From Discontinued Operations | - | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |
| Net Income | (20.27M) | (13.32M) | (12.98M) | (22.39M) | [{"date":"2022-12-31","value":-2027500000,"profit":false},{"date":"2023-12-31","value":-1331600000,"profit":false},{"date":"2024-12-31","value":-1297800000,"profit":false},{"date":"2025-12-31","value":-2238600000,"profit":false}] | |
| EPS (Diluted) | (295.23) | (112.55) | (51.40) | (32.06) | [{"date":"2022-12-31","value":-29523.45,"profit":false},{"date":"2023-12-31","value":-11255.36,"profit":false},{"date":"2024-12-31","value":-5140.03,"profit":false},{"date":"2025-12-31","value":-3205.67,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
| CNSY | |
|---|---|
| Current Ratio | 2.27 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| CNSY | |
|---|---|
| ROA (LTM) | -73.82% |
| ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| CNSY | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.40 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.60 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| CNSY | |
|---|---|
| Trailing PE | 0.17 |
| Forward PE | NM |
| P/S (TTM) | 4.92 |
| P/B | 2.20 |
| Price/FCF | NM |
| EV/R | 18.19 |
| EV/Ebitda | NM |
Cerenome, Inc. (CNSY) share price today is $3.68
Yes, Indians can buy shares of Cerenome, Inc. (CNSY) on Vested. To buy
Yes, you can purchase fractional shares of Cerenome, Inc. (CNSY) via the Vested app. You can start investing in Cerenome, Inc. (CNSY) with a minimum investment of $1.
You can invest in shares of Cerenome, Inc. (CNSY) via Vested in three simple steps:
The 52-week high price of Cerenome, Inc. (CNSY) is $23.5. The 52-week low price of Cerenome, Inc. (CNSY) is $2.9.
The price-to-earnings (P/E) ratio of Cerenome, Inc. (CNSY) is 0.1716
The price-to-book (P/B) ratio of Cerenome, Inc. (CNSY) is 2.20
The dividend yield of Cerenome, Inc. (CNSY) is 0.00%
The market capitalization of Cerenome, Inc. (CNSY) is $25.47M
The stock symbol (or ticker) of Cerenome, Inc. is CNSY
Consider the share price of Cerenome, Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Cerenome, Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Cerenome, Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Cerenome, Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Cerenome, Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Cerenome, Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
